MaaT Pharma raise 18m to advance clinical pipeline
MaaT Pharma SA has announced 18m Series B financing to boost its microbiome biotherapeutics pipeline.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Stilla raises 20m in series B financing round
/in News/by Thomas GabrielczykFrench Stilla Technologies SA raised 20m in a Series B funding to boost digital PCR-based genetic testing.
Valneva raises US$85m
/in News/by Thomas GabrielczykFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
EMA greenlights 15 new meds
/in News/by Thomas GabrielczykThe EMAs human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
Sleeping sickness target deciphered
/in News/by Thomas GabrielczykResearchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
UK researchers present dengue virus transmission map
/in News/by Thomas GabrielczykScientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
AMR: IMIs Enable project reaches endpoints
/in News/by Thomas GabrielczykThe ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
MercachemSyncom, Bionetix, and ProQinase ink AML contract
/in News/by Thomas GabrielczykBionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
iOnctura SA bags 15m in Series A round
/in News/by Thomas GabrielczykMerck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
BioNTech acquires Neon at cheapest for $67m
/in News/by Thomas GabrielczykmRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.